Q: Is decreased libido during menopause normal?
A: Yes. Hormones shift during perimenopause and menopause which changes how your body and sex work, both physically and mentally. Lower libido, also known as sex drive or desire, is common, and it is treatable.
Q: What causes low sex drive in perimenopause and menopause?
A: Changes in estrogen and androgen activity (testosterone) may contribute to changes in sexual function and desire. Other menopause-driven symptoms like poor sleep, mood changes, and pain during intercourse can accumulate and decrease desire even more. This is usually a multi-factored problem for most women.
Q: Can hormone therapy help with libido?
A: For many women, yes. Estrogen therapy can treat the physical causes that contribute to low libido, such as vaginal dryness and pain. But testosterone therapy alone has been scientifically proven to increase desire for some women.
Q: Is testosterone therapy safe and effective for women?
A: Research shows it can improve libido for many women, and the side effects are typically mild when it is dosed correctly by a clinician. It is not FDA approved for women in the United States, so it is prescribed off label.
Q: What does testosterone therapy to treat low sexual desire entail?
A: There are several options, all off label, for women, including a low dose cream formulated specifically for women that you apply daily to the inner thigh or forearm.
Q: What can I do besides hormones?
A: Non-hormonal prescriptions, pelvic floor therapy, and improving sleep and stress challenges all help. Some of these work well on their own, while others work best in combination with hormone therapy.
Low libido during menopause is not a mystery, and it is not a character flaw. It comes from specific, measurable changes within your body. Here is what is actually happening.
There are three hormones that drive most of what happens to your libido during the menopause transition: estrogen, testosterone, and progesterone.
Estrogen keeps the tissue in your vagina and vulva thick, elastic, and sufficiently lubricated. As estrogen drops during perimenopause and decreases even further after menopause, that tissue gets thinner and drier. Intercourse can start to hurt. And when intercourse hurts, the desire for it decreases quickly.
Testosterone is often called a "male hormone," but your ovaries and adrenal glands produce it as well. It plays a direct role in female sex drive. Testosterone levels start gradually declining in your 30s and 40s, well before menopause itself. By their 50s, many women have testosterone levels low enough to affect desire.
Progesterone does not directly drive libido the way estrogen and testosterone do, but its fluctuations during perimenopause disrupt both sleep and mood, which indirectly affects libido.
Put simply: as these three hormones shift and change, your body has less biological "fuel" for desire, and the physical experience of sex can become less comfortable or even painful.
Hormones are the starting point, but they are not the entire picture. Three other factors commonly accumulate in addition to the hormonal changes:
Sleep. Hot flashes and night sweats disrupt sleep, sometimes waking you several times a night without you being fully aware. Poor sleep decreases testosterone production and leaves you too exhausted to desire sex, even if your hormones were otherwise normal.
Mood. Perimenopause and menopause increase the risk of developing anxiety and depression, both of which are well documented to decrease libido. This does not reflect a personal failing. It is a direct, physiological effect of hormone withdrawal on brain chemistry.
Body image. Weight redistribution, skin changes, and other visible effects of this transition can affect how women feel about themselves, which in turn affects desire. This is a genuine factor, not a vanity issue, and it is worth identifying with honesty.
None of these factors work in isolation. A woman who is not sleeping, feeling down, and is in physical pain during intercourse is navigating multiple compounding issues, not one. That is exactly why treatment typically needs to address more than a single symptom.
If sex hurts, your desire for it decreases. That is not complicated to understand, but the underlying cause often gets overlooked or misdiagnosed.
Genitourinary Syndrome of Menopause, or GSM, is the medical term for the changes that occur to your vagina, vulva, and lower urinary tract when estrogen decreases. In simple terms, the tissue gets thinner, drier, less flexible, and more fragile. This can cause burning, itching, dryness, and pain during intercourse. It can also cause increased urinary tract infections and a stronger urge to urinate.
GSM is not rare and it does not go away on its own. Unlike hot flashes, which often fade over time, GSM tends to worsen the longer estrogen remains low, because the tissue continues to thin without it. A recent systematic review of hormonal treatments for GSM confirmed the uplifting news: it responds very reliably to treatment.
Here is the part that often gets missed: for many women, low libido during menopause is not primarily a "desire" issue. It is a pain issue that comes across as a desire issue.
If intercourse has been painful the last few times, your body and brain start to anticipate that pain before anything even happens. That anticipation itself decreases arousal and desire. This makes the tissue even less prepared for intercourse, which makes it hurt even more. This turns into a cycle that repeats and worsens.
This matters because it changes where treatment should be started. If pain is the root cause, treating "low libido" directly, without treating the vaginal dryness and thinning tissue underpinning it, will not work. Restoring physical comfort usually has to come first.
HRT stands for hormone replacement therapy. It means giving your body some of the estrogen, progesterone, and sometimes testosterone, that it has stopped producing during menopause. We’re going to connect the different forms of HRT to their impact on libido.
Systemic estrogen is estrogen that travels through your entire bloodstream. It is usually delivered transdermally, meaning through your skin, in the form of a patch, cream, or gel. Oral estrogen is also systemic but is not the preferred form of treatment for many women. Systemic estrogen treats hot flashes, night sweats, bone health, and mood symptoms throughout your body, not in just a localized area.
Systemic estrogen can improve libido indirectly. If it improves your sleep and stabilizes your mood, your desire for sex often increases as a result. But systemic estrogen alone often isn’t enough, especially because it generally does not fully treat vaginal dryness and thinning, which is why many women need a second, more targeted treatment as well.
Local estrogen is delivered directly to the vaginal tissue, through a cream, tablet, ring, or suppository, instead of through the whole bloodstream. Because it works right where the problem is, it is very effective at reversing the thinning and dryness of GSM. This directly reduces pain during sex, which removes one of the biggest drivers of low libido described above.
The dose is much lower than systemic estrogen, and has minimal systemic absorption compared with systemic hormone therapy. That makes it an option clinicians consider for many women, including some who can't use systemic estrogen, such as women with a history of breast cancer. Your clinician can review your history to confirm what's right for you.
A review of hormonal treatments for GSM found that vaginal estrogen consistently improved dryness, pain during sex, and related symptoms across the studies examined. This lines up with what clinicians see in practice: local treatment reliably fixes the physical cause, which in turn restores comfort and often desire.
Testosterone is brought up in conversations about menopause and libido, and for good reason.
Testosterone acts more directly on sexual desire itself than estrogen does. Multiple clinical studies have found that testosterone therapy improves sexual desire, arousal, and satisfaction in postmenopausal women, particularly in women diagnosed with Hypoactive Sexual Desire Disorder (HSDD). HSDD refers to persistent or recurrent low sexual desire that causes personal distress and is not better explained by another medical condition, medication, or other contributing factor.
The mechanism is straightforward: testosterone attaches to receptors, which are like small docking stations, in the brain and in body tissue involved in sexual response. In appropriately selected women with HSDD, correctly dosed testosterone therapy can improve sexual desire and related sexual function.
This idea is backed by a global consensus statement on testosterone therapy in women, written by a group of international menopause and hormone specialists who reviewed the evidence together. Additionally, a placebo-controlled trial tested testosterone against a placebo, which is an inactive treatment used for comparison, in postmenopausal women with low libido. Women who received testosterone had more satisfying sexual experiences than the women who received the placebo.
Testosterone therapy is not currently FDA-approved for women in the United States. It is approved for men, but not for women, even though the research supporting its use in women for low libido is strong.
Because of this, clinicians who prescribe testosterone for women do so "off label," which means they are prescribing an approved medication for a use that the FDA has not formally approved, based on clinical evidence and professional guidelines. Off-label prescribing is a common clinical practice when supported by appropriate evidence and professional guidance. It typically involves either a low, carefully measured dose of a product approved for men, or a compounded prescription made specifically for women at an appropriate dose.
At Inflexxion Health, our testosterone treatment is a custom formulated, low dose cream that is applied to the forearm or inner thigh. A cream allows for a more consistent level of medication, makes calibrating or stopping entirely easier, is more convenient to administer and more cost effective.
Most women who respond to testosterone therapy notice an improvement in their desire over 4 to 12 weeks, not overnight. Response varies, and not every woman notices a significant change. Clinicians should monitor symptoms, side effects, and serum testosterone (through lab testing) during treatment to help ensure levels do not exceed the physiologic premenopausal range.
Hormone therapy is not the only treatment option, and it is not right for every single woman. Some women cannot use hormones for medical reasons, while others simply prefer to try other approaches first.
Ospemifene is an oral selective estrogen receptor modulator (SERM) that has tissue-selective estrogen agonist and antagonist effects and is FDA-approved for moderate-to-severe dyspareunia and vaginal dryness associated with menopause. It treats pain during intercourse that is caused by GSM, and is an option for women who cannot or do not want to use estrogen.
Vaginal prasterone (DHEA) is FDA-approved for moderate-to-severe dyspareunia (painful sex) due to menopause. and converts into small amounts of estrogen and testosterone directly in the vaginal tissue. It treats the same dryness and pain symptoms that local estrogen does, but through a different mechanism.
Both of these are legitimate, FDA-approved prescription options, not supplements, and both require a consultation with a clinician to determine compatibility.
There is a lot of noise in this space. Here is what has real evidence supporting it, and what primarily does not.
Backed by evidence: treating sleep problems directly (through hormone therapy or other means), addressing anxiety or depression with appropriate treatment, and pelvic floor physical therapy for women experiencing pain, which can retrain tissue and muscle response over time.
Weak or unproven: most libido supplements sold over the counter have little to no reliable evidence behind their claims. Some may help a small amount of women through a placebo effect, but they are not a replacement for treating the actual hormonal or physical causes.
The pattern here is consistent: treatments that address a specific, identified cause (dryness, sleep, mood, hormone levels) tend to be successful. Treatments that promise a general "libido boost" with no clear mechanism tend not to be.
"Talk to your doctor" is not useful advice on its own if you don't know what questions to ask. Here are specific questions worth bringing up at your next visit:
Asking these direct questions tends to get you a more useful answer and solutions than a general "my sex drive is low" without the specifics supporting it.
Most primary care physicians and OB-GYNs receive very little formal training in menopause, which is a contributing factor as to why so many women receive vague or incomplete answers to very treatable problems. Menopause-focused specialists spend their time exclusively on this stage of life and its broad spectrum of symptoms, including sexual health.
Inflexxion Health's clinicians specialize in midlife women's health, offering personalized treatment, including hormone therapy and compounded prescriptions, through virtual visits with medication shipped directly to your door. If you've been going through menopause without real answers or solutions, talking with a menopause specialist is a concrete next step, not just another appointment.
Not usually, at least not the parts caused by ongoing decreased hormone levels. Hot flashes often fade over several years even without treatment, but GSM, the tissue thinning and dryness described earlier, tends to worsen over time without treatment rather than get better. Libido changes tied to that pain generally persist until the underlying cause is addressed and treated.
Yes, this is common and often overlooked. SSRIs and SNRIs, two common types of antidepressants, are well established to reduce libido and delay orgasm in a significant number of people who take them. If you're on one of these medications and also dealing with low libido, it's worth discussing with your provider whether or not the medication is contributing, and if an adjustment in medication makes sense.
At appropriately monitored doses, most women tolerate it well. The most commonly reported side effects are mild acne and increased facial or body hair growth, both of which are more likely to occur at higher doses and will typically improve when the dose is adjusted. Serious side effects are uncommon when levels are assessed over the time of use through bloodwork by a clinician.
It depends on the treatment. Local vaginal estrogen for pain and dryness often shows improvement within 2 to 4 weeks. Testosterone therapy for sexual desire typically takes 4 to 12 weeks to reflect a noticeable difference. Sleep and mood related improvements vary based on how quickly those underlying issues respond to treatment.
It can be either, or both, and they are not mutually exclusive.Sexual desire is influenced by biological, psychological, relational, and contextual factors, and more than one factor may be present at the same time. A thoughtful evaluation should include potential hormonal and physical contributors without assuming the problem is solely relational or psychological.
They help with comfort during intercourse in the moment, and vaginal moisturizers used regularly (not just during intercourse) can somewhat improve tissue comfort over time. But neither one reverses the underlying tissue thinning caused by low estrogen in the same way local estrogen, ospemifene, or prasterone can. They are a reasonable short-term option or supportive measure, not a substitute for treating the root cause.